AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
2min chapter
How a big biotech’s start-up gamble went wrong
Behind the Money
Illumina's Cost-Cutting Plan
The biotech stock boom that was happening at the height of the pandemic starts to fizzle out. Illumina is getting caught up in litigation with regulators about Grail. The company began to face tough competition from a crop of early stage companies. And by the end of 2022, we had Illumina announcing a cost-cutting plan.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode